553 related articles for article (PubMed ID: 31856912)
21. Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H; Ogimi T; Chan LF; Kamei Y
Oncology; 2020; 98(9):637-642. PubMed ID: 32474564
[TBL] [Abstract][Full Text] [Related]
22. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Okuyama Y; Hazama S; Nozawa H; Kobayashi M; Takahashi K; Fujikawa K; Kato T; Nagata N; Kimura H; Oba K; Sakamoto J; Mishima H
Jpn J Clin Oncol; 2011 Apr; 41(4):477-82. PubMed ID: 21303789
[TBL] [Abstract][Full Text] [Related]
23. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
[TBL] [Abstract][Full Text] [Related]
24. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Suenaga M; Fuse N; Yamaguchi T; Yamanaka Y; Motomura S; Matsumoto H; Hamamoto Y; Mizunuma N; Doi T; Hatake K; Iwasaki J; Ohtsu A
J Clin Pharmacol; 2014 May; 54(5):495-502. PubMed ID: 24382596
[TBL] [Abstract][Full Text] [Related]
28. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Iwasa S; Muro K; Morita S; Park YS; Nakamura M; Kotaka M; Nishina T; Matsuoka H; Ahn JB; Lee KW; Hong YS; Han SW; Cho SH; Zhang DS; Fang WJ; Bai L; Yuan XL; Yuan Y; Yamada Y; Sakamoto J; Kim TW
Cancer Sci; 2021 Nov; 112(11):4669-4678. PubMed ID: 34327766
[TBL] [Abstract][Full Text] [Related]
29. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
31. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Tsai HL; Chen YC; Yin TC; Su WC; Chen PJ; Chang TK; Li CC; Huang CW; Wang JY
Oncol Res; 2022 May; 29(1):47-61. PubMed ID: 35177165
[No Abstract] [Full Text] [Related]
33. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
34. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Manfredi S; Bouché O; Rougier P; Dahan L; Loriot MA; Aparicio T; Etienne PL; Lafargue JP; Lécaille C; Legoux JL; Le Malicot K; Maillard E; Lecomte T; Khemissa F; Breysacher G; Michel P; Mitry E; Bedenne L
Mol Cancer Ther; 2015 Dec; 14(12):2782-8. PubMed ID: 26494856
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
36. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
[TBL] [Abstract][Full Text] [Related]
37. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
39. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
[TBL] [Abstract][Full Text] [Related]
40. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]